Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) will present a company overview and participate in a Q&A session at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will include an update on unaudited fourth quarter and full year 2023 global net product revenues.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 42^nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2023 global net product revenues.

A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240102586216/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

What is the date of the 42nd Annual J.P. Morgan Healthcare Conference where Alnylam Pharmaceuticals, Inc. will be presenting?

Alnylam Pharmaceuticals, Inc. will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.

Where will the presentation take place?

The presentation will take place at The Westin St. Francis in San Francisco.

Where can I access the live audio webcast of the presentation and Q&A session?

The live audio webcast will be available on the Investors section of the Company’s website, www.alnylam.com/events.

When will the replay of the presentation be available on the Alnylam website?

The replay will be available on the Alnylam website within 48 hours after the event.